Innovative Therapeutics in Oncology and Neuroscience

Efgartigimod Phase 3 ADAPT Data Showed Fast, Deep, and Durable Responses for Patients with gMG Approved 37 Minimal Symptom Expression (AChR Ab+ patients, first cycle) 80% 70% 40% of Efgartigimod Patients Achieved 60% Minimal Symptom Expression 1 50% 40.0% 40% Durable Clinical Benefit Duration of Response (AChR Ab+ Efgartigimod responders², first cycle) Potential for Individualized Dosing Max Response: 25 Weeks 12 Weeks or More 34.1% 8 Weeks or More 30% P < 0.0001 6 Weeks or More 20% 11.1% 10% 4 Weeks or More N=25/65 N=7/63 0% Efgartigimod Placebo 56.8% 0% 50% 88.6% Efgartigimod Demonstrated Significant Magnitude of Benefit AChR Ab+ Patients, Cycle 1 18765432 MG - ADL 14.3% 0.0% 20.6% 1.7% 27.0% 3.3% 39.7% 8.3% 55.6% 11.7% 63.5% 23.3% 73.0% 36.7% 77.8% 48.3% QMG 10 09876543 25.8% 0.0% 33.9% 0.0% 37.1% 1.7% 45.2% 1.7% 50.0% 5.2% 59.7% 12.1% 64.5% 15.5% 74.2% 25.9% 100% Efgartigimod Placebo 100.0% NMPA approved the BLA for gMG (IV) in China in June 2023; Potential NMPA approval for gMG (SC) in 2024 Source: argenx corporate presentation, January 2021. Notes: (1) Minimal Symptom Expression: MG-ADL = 0 (no symptoms) or 1; (2) Responder defined as at least 4 consecutive weeks. Clinical Data - Autoimmune

View entire presentation